…

The shift toward simplified and long-acting antiretroviral strategies reflects a broader recognition that the success of HIV treatment is no longer measured solely by virological suppression, but also by how well regimens fit into the lives of the people who take them. Early combination antiretroviral therapy required patients to manage multiple pills on strict schedules, often with demanding dietary requirements and considerable pill-related side effects. Over time, fixed-dose combinations reduced daily regimens to a single tablet, dramatically improving adherence and quality of life. The current generation of strategies goes a step further by questioning whether daily oral dosing is necessary at all, exploring instead whether injections administered every one to two months, or even longer intervals, can maintain the same degree of viral control. This evolution is not merely a matter of convenience; it represents a fundamental rethinking of how antiretroviral drugs are delivered, monitored, and integrated into health systems.

Understanding why these strategies are possible requires an appreciation of the HIV replication cycle and the drug targets that have been developed against it. HIV enters target cells through interaction between the viral envelope protein and cellular receptors, then converts its RNA genome into DNA through reverse transcription, integrates that DNA into the host genome, and subsequently produces new viral particles. Each stage of this cycle offers a potential point of intervention. Nucleoside and nucleotide reverse transcriptase inhibitors mimic natural nucleotides and terminate viral DNA synthesis. Non-nucleoside reverse transcriptase inhibitors bind allosterically to the reverse transcriptase enzyme and distort its active site. Integrase strand transfer inhibitors block the insertion of viral DNA into the host genome, while protease inhibitors prevent the maturation of newly formed virions. Entry inhibitors and capsid inhibitors target earlier or structural stages of the viral life cycle. The pharmacological properties of these drug classes differ substantially, and it is these differences that determine which agents can be formulated for extended-release delivery and which are better suited to oral daily dosing.

Long-acting formulations rely on nanocrystal technology that allows drugs to be injected as aqueous suspensions which form a depot in muscle tissue and release the active compound slowly into the bloodstream. For a drug to be suitable for this approach, it must have a long elimination half-life, high potency, and a therapeutic window wide enough that trough concentrations remain far above the levels needed to suppress replication. The integrase inhibitor cabotegravir and the non-nucleoside reverse transcriptase inhibitor rilpivirine were the first agents to meet these criteria in a combination approved for clinical use. Their pharmacokinetic profiles allow plasma concentrations to remain suppressive for weeks after a single intramuscular injection, but they also create a distinctive pharmacological challenge known as the tail phase. After injections are discontinued, drug levels decline gradually over an extended period rather than disappearing quickly as oral drugs do. During this prolonged tail, concentrations may fall below the threshold required for full suppression while still remaining high enough to exert selective pressure, creating a window in which partially resistant viral strains could theoretically emerge if a patient is exposed to circulating virus with resistance mutations.

This pharmacokinetic characteristic shapes much of the clinical guidance surrounding long-acting therapy. Patients who discontinue injectable regimens are generally advised to transition to an oral suppressive regimen that overlaps with the tail phase, ensuring that virological suppression is maintained until long-acting drug levels fall below meaningful concentrations. The duration of the tail varies between individuals and can be influenced by body weight, drug metabolism, and injection site characteristics, which adds a layer of individual variability that clinicians must account for when planning transitions. Missed injections present a related concern, since delays in scheduled dosing can allow drug concentrations to drift into ranges that are neither fully suppressive nor safely negligible. Structured follow-up, clear patient education about the importance of injection timing, and contingency plans for missed doses are therefore essential components of any long-acting treatment program.

Resistance considerations in the context of simplified regimens differ meaningfully from those associated with traditional combination therapy. Standard first-line oral regimens typically combine two or three drugs from different classes, providing a genetic barrier to resistance because the virus would need to acquire multiple mutations simultaneously to escape suppression. Long-acting injectable therapy with cabotegravir and rilpivirine involves only two agents, and both have well-characterized resistance profiles. Integrase strand transfer inhibitors can lose efficacy in the presence of mutations that alter the integrase active site, and second-generation agents such as dolutegravir and bictegravir were developed specifically to maintain activity against viruses carrying first-generation integrase resistance. Rilpivirine, as a non-nucleoside reverse transcriptase inhibitor, is vulnerable to mutations that also confer cross-resistance to other drugs in its class, including efavirenz and nevirapine. Pretreatment resistance testing therefore plays a more prominent role in patient selection for long-acting regimens than it does for standard first-line therapy, where the genetic barrier of triple-class combinations provides more inherent protection.

Patient selection criteria for long-acting switch strategies have been informed by the clinical trials that established their efficacy. These trials generally enrolled adults with sustained virological suppression on stable oral regimens, without prior treatment failure, without active hepatitis B coinfection, and without evidence of resistance to the components of the injectable regimen. Body mass index and weight thresholds were also applied in some trial protocols because extreme body weight can affect drug distribution and injection site tolerability. Adherence history is another important consideration, since patients who struggled with daily oral dosing may face different challenges with bimonthly clinic visits, and the assumption that long-acting therapy automatically solves adherence problems is not always borne out in practice. Some patients find the requirement to attend clinic appointments every one to two months more burdensome than taking a daily pill at home, particularly those who live far from healthcare facilities or have inflexible work schedules.

Hepatitis B virus coinfection represents a specific and important consideration in regimen simplification. The nucleoside analogues lamivudine and emtricitabine, which are backbone components of most standard oral antiretroviral regimens, also have activity against hepatitis B. Removing these agents from a regimen in a coinfected patient risks hepatitis B reactivation, which can lead to severe hepatic flares, liver failure, and death. Current guidance therefore generally recommends that patients coinfected with hepatitis B either remain on regimens containing agents with anti-hepatitis B activity or receive separate hepatitis B-directed therapy if the antiretroviral regimen is simplified to agents lacking this coverage. This constraint limits the applicability of certain two-drug and long-acting strategies in coinfected populations and underscores the importance of screening for hepatitis B before any regimen switch is undertaken.

On the prevention side of the continuum, long-acting preexposure prophylaxis has emerged as a significant addition to the available options. Daily oral tenofovir-based preexposure prophylaxis is highly effective when taken consistently, but real-world effectiveness depends heavily on adherence, which varies across populations and circumstances. Cabotegravir injections administered every two months provide prevention coverage that does not depend on daily pill-taking, and clinical trials demonstrated substantially higher effectiveness compared with daily oral tenofovir-emtricitabine, largely attributable to superior adherence to the injection schedule. However, the same pharmacokinetic tail that complicates treatment discontinuation also applies to prevention. During the initiation phase, oral lead-in dosing is sometimes used to achieve protective concentrations before the first injection, and during the tail phase after discontinuation, individuals remain exposed to the risk of infection with drug concentrations that may be insufficient for full protection but sufficient to select for resistance if breakthrough infection occurs. Individuals using long-acting preexposure prophylaxis who discontinue injections need clear guidance about when protection wanes and when alternative prevention strategies should be resumed.

The redistribution of treatment burden described in the source review is a concept worth examining closely. Simplified regimens reduce the number of pills a patient must manage, but they simultaneously increase the demands placed on healthcare delivery systems. Injectable therapy requires trained personnel to administer injections, clinic infrastructure to accommodate regular visits, cold chain or storage considerations for drug supplies, and scheduling systems that can reliably bring patients back at appropriate intervals. Virological monitoring requirements may become more frequent rather than less, since confirming that a switch to a simplified regimen has maintained suppression is essential before and after the transition. Resistance assessment before switching adds laboratory costs and turnaround time. For health systems in resource-limited settings, these infrastructure demands can be substantial, and the availability of long-acting options may initially be concentrated in well-resourced urban centers, potentially widening disparities in access to advanced HIV care.

Implementation challenges also extend to the training and workflow adjustments required of clinical teams. Nurses and other personnel who administer injections need education on injection technique, site rotation, and the management of local reactions. Injection site reactions, while generally mild, are among the most commonly reported adverse events with long-acting cabotegravir and rilpivirine, and patient counseling about what to expect can improve tolerability and reduce unnecessary discontinuation. Scheduling systems must account for the acceptable dosing windows around each injection date, since clinical trials established specific ranges within which doses can be given without compromising efficacy. Health systems that lack flexible appointment scheduling may struggle to keep patients within these windows, particularly for populations with unstable housing, employment insecurity, or transportation barriers.

Two-drug oral regimens represent another branch of the simplification effort that operates alongside long-acting injectables. Regimens pairing an integrase inhibitor with a single nucleoside backbone agent, or with agents from other classes, have been evaluated as alternatives to standard three-drug therapy in patients who meet specific criteria. These strategies reduce pill burden and drug exposure while maintaining suppression in appropriately selected patients, but they share with long-acting therapy the need for careful pretreatment assessment of resistance, hepatitis B status, and virological history. The evidence base for two-drug regimens has grown considerably, and they are now established options for switch strategies in suppressed patients, though their role as initial therapy remains more constrained and dependent on individual patient characteristics.

Looking ahead, the source review points toward next-generation antiviral strategies that could further expand the long-acting paradigm. Agents with even longer dosing intervals are in development, including broadly neutralizing antibodies and capsid inhibitors formulated for extended-release delivery. Islatravir, a nucleoside reverse transcriptase translocation inhibitor with an exceptionally long half-life, has been studied as a component of monthly and less frequent oral regimens, though clinical trials revealed dose-dependent effects on lymphocyte counts that required careful dose selection. Implantable devices that release antiretroviral drugs over months offer another delivery modality that could reduce the frequency of clinic visits even further. Broadly neutralizing antibodies targeting the HIV envelope, whether used alone or in combination, represent a class of agents whose long plasma half-lives make them natural candidates for extended-interval administration, and early studies have explored their role in both treatment and prevention contexts.

The development of these next-generation strategies will need to contend with the same principles that shaped the current generation. Potency, pharmacokinetic durability, resistance barriers, safety profiles, and the practicalities of healthcare delivery will all determine which agents succeed in clinical practice. The experience with cabotegravir and rilpivirine has established a template for how long-acting agents are evaluated, but it has also revealed the importance of the tail phase, the significance of adherence to injection schedules, and the need for robust patient selection criteria. As the number of long-acting options grows, clinicians will face increasing complexity in matching individual patients to appropriate strategies, weighing the reduced burden of daily pill-taking against the increased burden of regular clinic attendance, monitoring requirements, and the pharmacokinetic uncertainties inherent in extended-release delivery.

Ultimately, the trajectory described in the source review suggests that the future of HIV care will be characterized by greater individualization rather than by a single dominant approach. Some patients will thrive on long-acting injectables and prefer the freedom from daily dosing. Others will continue to favor oral regimens that they can manage at home. Still others may benefit from hybrid approaches that combine oral and injectable components, or from simplified two-drug oral strategies that reduce drug exposure while maintaining suppression. The role of the clinician in this landscape is to assess each patient’s circumstances, preferences, virological history, coinfection status, and resistance profile, and to recommend the strategy that offers the best balance of efficacy, safety, and quality of life. Continued research into patient-reported outcomes, long-term safety data, and real-world implementation experience will be essential to refine these recommendations and ensure that the promise of simplified and long-acting antiretroviral strategies is realized equitably across the diverse populations affected by HIV.

Subject of Research: Virology

Article Title: Simplified and long-acting antiretroviral strategies across the HIV prevention and care continuum: clinical applications and future directions

Article References: Li, W., Liu, M., Wang, J., Liu, H., Du, L., & Tang, H. (2026). Simplified and long-acting antiretroviral strategies across the HIV prevention and care continuum: clinical applications and future directions. Virology Journal. https://doi.org/10.1186/s12985-026-03335-7

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03335-7

Keywords: HIV, antiretroviral therapy, long-acting therapy, treatment simplification, preexposure prophylaxis, virology, Simplified, long-acting, antiretroviral, strategies, across, prevention